Notice of Proposed Sale · 144
Dianthus Therapeutics, Inc.
DNTHNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Dianthus Therapeutics, Inc.
- Issuer CIK
- 0001690585
- SEC file number
- 001-38541
- Phone
- 9299994055
- Person for whose account securities are to be sold
- ADAM VENESS
- Relationships to issuer
- Officer
- Street
- 7 Times Square, 43rd Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10036
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 3,833 | 421,323.36 | 55,934,378 | 08/07/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/07/2026 | Exercise of Stock Options | Issuer | 3,833 | N | 08/07/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for ADAM M VENESS | Common | 06/17/2026 | 30,000 | 2,424,033.00 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for ADAM M VENESS
- Street
- 7 Times Square, 43rd Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10036
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/07/2026
- Signed
- /s/ Adam Veness
- Plan adoption dates
- 03/18/2026
Company context
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.